SignatureFD’s Stoke Therapeutics STOK Stock Holding History

SignatureFD’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72K	Sell	83 -27	-25%	-$866	﹤0.01%	3069
2026 Q1	$3.58K	Buy	110 +27	+33%	+$885	﹤0.01%	2885
2025 Q4	$2.63K	Hold	83	–	–	﹤0.01%	2896
2025 Q3	$1.95K	Buy	+83	New	+$1.42K	﹤0.01%	2959
2023 Q3	–	Sell	-1,031	Closed	-$11K	–	3301
2023 Q2	$11K	Buy	1,031 +5	+0.5%	+$53	﹤0.01%	2190
2023 Q1	$8.55K	Buy	1,026 +458	+81%	+$4.13K	﹤0.01%	2285
2022 Q4	$5.24K	Buy	568 +451	+385%	+$4.69K	﹤0.01%	2460
2022 Q3	$2K	Hold	117	–	–	﹤0.01%	2848
2022 Q2	$2K	Sell	117 -445	-79%	-$6.76K	﹤0.01%	2806
2022 Q1	$12K	Buy	+562	New	+$11.3K	﹤0.01%	2087
2021 Q4	–	Sell	-33	Closed	-$1K	–	3270
2021 Q3	$1K	Buy	+33	New	+$920	﹤0.01%	2926

Other funds holding STOK

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

GIM

Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SignatureFD's STOK Position: Q2 2026 in Review

SignatureFD reduced its Stoke Therapeutics (STOK) stake by 25% in Q2 2026, selling an estimated $866 and leaving 83 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #3069.

SignatureFD first reported a position in STOK in Q3 2021 and has held it in 11 quarters since. The position peaked at $12K in Q1 2022. 20 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

SignatureFD held 83 shares of Stoke Therapeutics worth $2.72K as of Q2 2026.
SignatureFD sold 27 Stoke Therapeutics shares in Q2 2026, an estimated $866.
Stoke Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3069 holding.
SignatureFD first reported a position in Stoke Therapeutics in Q3 2021 and has held it in 11 quarters since.
SignatureFD's Stoke Therapeutics position peaked at $12K in Q1 2022.
20 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.